No Tariff for Pharma Firms with US Facilities, Says Trump as 100% Duty on Branded Drug Imports Kicks In

Published On 2025-09-26 16:15 GMT | Update On 2025-09-26 16:15 GMT

New Delhi: Branded and patented pharmaceutical imports will face a 100% import duty in the United States from October 1, 2025, President Donald Trump announced. However, companies that have already started building drug manufacturing plants in America will be spared.

According to Trump, pharma firms that have “broken ground” or are “under construction” with new U.S. drug production facilities will not fall under the tariff plan. “There will, therefore, be no Tariff on these Pharmaceutical Products if construction has started,” he clarified.

The announcement is part of a broader tariff package. Imports of heavy trucks will attract a 25% duty, kitchen cabinets and bathroom vanities 50%, and upholstered furniture 30%. The pharmaceutical levy, however, has drawn the most attention because of its potential impact on global supply chains.

Also Read:Trump signs executive order to lower US drug prices

Indian and multinational pharmaceutical companies are now evaluating the impact of the move. Many firms already have U.S. manufacturing investments or are planning to build facilities, which could secure their exemption from the new duty.

According to a recent Financial Express report, the exemption reflects Trump’s push to bring back domestic drug manufacturing and reduce dependence on foreign production. Industry analysts suggest that while the rule offers relief to companies with U.S. plants, it could also accelerate investment decisions among others that want to maintain market access.

The tariff move, set to take effect in October, is expected to reshape pharmaceutical trade, with the full impact depending on enforcement and how quickly firms respond with new U.S.-based production.

Also Read:Imported Devices Face 7.5-10% Duty, Domestic Devices GST at 12%, Govt Clarifies

Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Parthika Patel

Parthika Patel has completed her Graduated B.Pharm from SSR COLLEGE OF PHARMACY and done M.Pharm in Pharmaceutics. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

No Tariff for Pharma Firms with US Facilities, Says Trump as 100% Duty on Branded Drug Imports Kicks In

Similar News

Online Pharmacy, 2 Indians Sanctioned by US for Fentanyl-Laced Pill Trafficking

Setback to Novartis: Delhi HC Rejects Cross-Examination Request in Post-Grant Patent Dispute

CDSCO Panel Asks Takeda to Submit Full Phase III Data on Dengue Tetravalent Vaccine

Bharat Biotech Gets SEC Nod to Begin Phase III Trial of Inactivated Chikungunya Vaccine

Sanofi India appoints Haresh Vala as Company Secretary, Compliance Officer

Abbott India's Goa Plant Director Munish Prashar to resign

Eli Lilly Inluriyo gets USFDA nod for adults with advanced breast cancer